Has Joel Schlessinger, MD received payments from drug or device companies?

Yes. Drug and device makers reported $89,201 in general payments to Joel Schlessinger, MD across 173 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Joel Schlessinger, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Joel Schlessinger, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Joel Schlessinger, MD

Dermatology · Omaha, NENPI 1720085582

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $56,281 of the $89,201 with a category attached, or 63.1%. AbbVie accounts for 68.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $53,705 and has fallen 88.2% since, to $6,313 in 2025. Among dermatology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$89,201in general payments, 2019–2025

Across 173 payments — averaging $515.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$61K
Galderma Laboratories, L.p.$16K
Pfizer$6K
Nielsen Biosciences, Inc.$4K
Novartis$1K
Merz North America, Inc.$1K
plus $293 from 7 others

$5,605,064in research payments, 2019–2025

Across 1,182 payments — averaging $4742.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$1.5M
Novartis$801K
Pfizer$566K
Eli Lilly$358K
Aclaris Therapeutics, Inc.$274K
Amgen$250K
plus $1.9M from 21 others

What the payments were for

Consulting fees$56,28163%
Speaking & faculty fees$7,4008%
Travel & lodging$20,19123%
Food & beverage$5,3286%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	100	$60,908
Galderma Laboratories, L.p.	37	$15,688
Pfizer	7	$5,590
Nielsen Biosciences, Inc.	1	$4,050
Novartis	6	$1,403
Merz North America, Inc.	9	$1,268
Dermavant Sciences, Inc.	6	$179
Boehringer Ingelheim	2	$34
Arcutis Biotherapeutics, Inc.	1	$19
Regeneron Healthcare Solutions, Inc.	1	$18
Botanix SB Inc	1	$16
Sanofi	1	$14
E.r. Squibb & Sons, L.L.C.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BOTOX COSMETIC$43,311
BOTOX$5,576
EUCRISA$4,800
Candin$4,050
AKLIEF$150
EPIDUO FORTE$150
ORACEA$150
VTAMA$103

How this compares

$89,201 in reported general payments places this provider in the 95th percentile of 68 dermatology providers in Nebraska.

See all dermatology providers in Nebraska →

Medicare billing

Part B allowed, 2024

$225,651

Medicare patients

432

Services billed

4,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	11	$70,591
Betamethasone Dipropionate	83	$3,747
Fluocinonide	70	$3,582
Cephalexin	384	$3,225
ValacyclovirValacyclovir Hcl	55	$2,521
Minocycline Hcl	161	$2,403
Imiquimod	49	$2,143
Ketoconazole	109	$1,506
Triamcinolone Acetonide	98	$1,434
Metronidazole	28	$1,348
Fluconazole	88	$1,144
Terbinafine Hcl	162	$1,107
Mupirocin	145	$1,057
Econazole Nitrate	26	$752
Rifampin	13	$447

Paid to pharmacies, not to this prescriber.

Other dermatology in Omaha

Rachel PersonOmaha$98K
Erin BarrettOmaha$96K
Mathew DaveyOmaha$35K
Gage RenschOmaha$11K
Herschel StollerOmaha$10K
Deirdre StolmeierOmaha$10K
Melissa DarlingOmaha$10K
Christopher HuerterOmaha$7K
Tina KinsleyOmaha$7K
Sara StephensonOmaha$7K

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →